Tuberous sclerosis complex (TSC) is an autosomal disease caused by inactivating mutations in either of the tumor suppressor genes TSC1 or TSC2. TSC-associated tumor growth is present in multiple tissues and organs including brain, kidney, liver, heart, lungs, and skin. In the kidney, TSC angiomyolipomas have aberrant vascular structures with abnormal endothelial cells, suggesting a role for endothelial mTORC1 function. In the current report, a genetically engineered mouse model (GEMM) with a conditional knockout allele of Tsc1 with a Darpp32-Cre allele displayed accelerated formation of both kidney cystadenomas and paw hemangiosarcomas. All mutant mice developed hemangiosarcomas on multiple paws by 6 weeks of age. By 16 weeks of age, the average mutant hind paw was 4.0 mm in diameter, nearly double the size of control mice. Furthermore, the hemangiosarcomas and kidney cystadenomas were responsive to intraperitoneal rapamycin treatment. Immunoblotting and immunostaining for phospho-S6 (pS6) and phospho-CAD showed that the effect of rapamycin on tumor size was through inhibition of the mTOR signaling pathway. Finally, elevated VEGF mRNA levels were also observed in hemangiosarcoma specimens. Because paw hemangiosarcomas are easily detectable and scorable for size and growth, this novel mouse model enables accelerated in vivo drug testing for therapies of TSC-related tumors.
Introduction
Tuberous sclerosis complex (TSC) is a genetic disorder due to an inactivating mutation in either TSC1 or TSC2. The protein products of TSC1 and TSC2, hamartin and tuberin, respectively, form a heterodimeric complex that inhibits the mTOR complex 1 (mTOR) pathway via RHEB-GTP modulation (1, 2) . Activation of mTOR primarily regulates cell size and proliferation through promotion of translation (1) . Germline TSC1 or TSC2 mutations are complemented by second-hit loss of the wild-type allele leading to hyperactive mTOR activity, which results in the growth of tumors in brain (subependymal nodules and giant cell astrocytomas), kidney (renal angiomylipoma), and lung (pulmonary lymphyangioleiomyomatosis; refs. [3] [4] [5] . In addition to tumor growth, a combination of intellectual disability, epilepsy, and autism occurs in a majority of individuals with TSC (2) . Most tumors that arise due to TSC are of a benign phenotype (4) . However, renal angiomyolipomas can proliferate, and subsequent renal complications are cited as the most common cause of death in adult patients with TSC. Thus, therapies that inhibit hyperactive mTOR pathway are candidates for treatment of TSC-related tumors.
Rapamycin and related compounds (rapalogues) have been studied with regard to the inhibition of mTOR and treatment of TSC-related tumor growth (3, 6) . In multiple murine models of TSC, treatment of TSC-related tumors is effective in reducing tumor size (7) (8) (9) . Clinically, rapalogue treatment has been shown to result in regression of both renal angiomyolipomas (10, 11) and subependymal giant cell astrocytomas (12, 13) . However, rapalogue treatment does not lead to tumor elimination, and cessation of treatment results in re-growth of tumors (10, 13, 14) . Other drawbacks to the use of rapamycin are side effects ranging from diarrhea, stomatitis, respiratory infection, and pyelonephritis (10) . Hence, identification of more efficacious therapies is desirable to further the treatment of TSC-related tumor growth and subsequent clinical management.
Both cell-based and animal models have been used to identify therapeutics for treatment of TSC-related tumors (15) . However, both Tsc1 þ/À and Tsc2 þ/À mice develop kidney cystadenomas and liver hemangiomas as their main phenotype, tumors which do not match the pathology of human TSC (16) (17) (18) . Furthermore, the development of kidney and liver tumors in murine models can take from 4 to 15 months of age with varying incidence rates (17, 18) . In the present study, by combining a conditional knockout allele of Tsc1 with a Darpp32-Cre allele, we created a mouse that develops kidney cystadenomas and hemangiosarcomas in the extremities on an accelerated time scale. Furthermore, we tracked paw hemangiosarcoma development by simple observation during rapamycin treatment, demonstrating its use as an easily scorable measure of tumor response. Our results demonstrate the usefulness of this model for preclinical testing of novel drugs for the treatment of TSC-related tumors.
Materials and Methods
Breeding strategy and phenotyping All animal procedures and protocols were approved by the Institutional Animal Care and Use Committee (IACUC) and Animal Resources at Children's Hospital (ARCH). Mouse experiments were performed on a mixed strain background. Mice bearing the loxP-flanked Tsc1 allele (Tsc1c/c; ref. 19 
Tumor measurements
An observer (S. Goldman) blind to the genotype performed paw measurements. Hind paw diameter was measured using a 0.1-mm resolution caliper in the plantar to dorsal dimension. Mean paw diameters were determined by the average of both left and right paws. Paw diameters were measured biweekly until death. Individual mice were euthanized when paw diameter of !5 mm, weight loss of !20%, or greatly extreme lethargy was seen.
Treatment protocol
All mouse treatments commenced when the diameter of rear paw tumors averaged 4.0 mm. Mice treated with rapamycin (LC Laboratories, Cat. No: R-5000) were injected intraperitoneally at 6 mg/kg in 100 mL of vehicle solution (5% Tween 80, 5% Polyethyl Glycol) every other day for 1 month. For statistical comparisons, 1-and 2-way ANOVAs with subsequent Bonferroni corrections, log-rank survival, and 2-tailed Student t tests were performed using Prism (GraphPad Software, Inc., v5.0f). Alpha level for all analyses was equal to 0.05.
Histology
Standard hematoxylin and eosin (H&E) sections were prepared from mouse kidney and paws taken immediately after death of an animal. Sections were fixed in 10% formalin for 12 hours before staining. For cyst diameter measurements, an observer blind to the treatment and age statuses (S.H.T. Lammers) analyzed sections on 4Â magnifications. Cyst diameter measurements were taken by identifying the largest cross-sectional diameter of a defined, enclosed cyst. For cyst counts, a cyst was counted if it was enclosed and greater than 3.5 Â 10 À3 mm in diameter. All imaging was performed on an Olympus BX51 microscope with a Qimaging Micropublisher 3.3 RTV camera and Qimaging QCapture software (Surrey).
Immunoblot analysis
Rear extremity tumor and kidney extracts were prepared in lysis buffer (20 mmol/L Tris-HCl, 140 mmol/L NaCl, 10 mmol/L NaF, 1 mmol/L Na 3 VO 4 , 1 mmol/L EDTA) and a Dounce homogenizer. Protein concentrations were determined by Bradford Assay (BioRad Laboratories), equal concentrations were separated by electrophoresis on 6%-12% Bis-Tris acrylamide gels and then transferred onto Immobilon-P PVDF membranes (EMD Millipore). Membranes were blocked with 5% nonfat dry milk in 1Â TBST (Tris-buffered saline and 10% Triton-X) for 1 hour at room temperature. Primary antibodies were diluted in 5% nonfat dry milk or 5% bovine serum albumin in 1Â TBST and applied to the membranes overnight at 4 C. Primary antibodies included P-CAD (Cell Signaling), CAD (Cell Signaling), p-S6-240 (Cell Signaling), S6-240 (Cell Signaling), and anti-tubulin (Abcam). After primary antibody incubation and washing with 1Â TBST, anti-mouse (Santa Cruz), or anti-rabbit (Rockland) horseradish peroxidase (HRP)-conjugated secondary antibodies were applied for 1 hour at room temperature in 5% nonfat dry milk solution of 1Â TBST. Supersignal West Pico and Dura Chemiluminescent (Thermo Fisher Scientific) signal solutions were used to detect antibody binding and signals were collected using an ImageQuant LAS 2000 imager (GE Healthcare).
Immunohistochemistry
Immunohistochemical analyses were performed on paraffinembedded sections of kidney and paw after 4% paraformaldehyde fixation for 12 hours or on frozen OCT-embedded tissues following 4% paraformaldehyde fixation. Phospho-S6 Ser 240/ 244 (Cell Signaling, Cat. No: 2215) was used as a primary antibody at 1:500 dilution. Secondary antibodies included Alexa Fluor 488 anti-goat and anti-rabbit used at 1:500 dilution. For Xgal staining, tissue was harvested and fixed with 4% paraformaldehyde overnight, followed by standard sucrose cryopreservation and OCT embedding. Sections were sliced and then stained in X-gal staining solution overnight at 37 C followed by counterstaining with Nuclear Fast Red as previously described (21) .
qPCR
All tissue samples from kidney and paws were extracted 1 week after the last day of treatment in a sterile fashion and immediately frozen in liquid nitrogen. RNA was precipitated by lysing tissue using TRIzol (Invitrogen) and a 22-gauge syringe followed by chloroform extraction. RNA was then reverse transcribed to cDNA and amplified as previously described for qPCR (22) . Amplification and quantification were run with VEGF-A, VEGF-C, VEGF-D, and GAPDH primers designed with Primer 3 and sequences were as follows: VEGF-A 5 0 -CCGAAACCATGAACT-TTCTGC-3 0 (forward) and 5
Results
A new TSC mouse model with rapid development of paw hemangiosarcoma Our intent in creating a Tsc1 cc Darpp-32-Creþ mice was to develop a unique TSC brain model with Tsc1 loss in striatal neurons (23) . Although DARPP-32 (dopamine and cAMP-regulated neuronal phosphoprotein 322 or protein phosphatase 1 regulatory subunit 1B2, gene name PPP1R1B) is expressed at highest levels in brain, it is also expressed in multiple other tissues, including pancreas, prostate, lung, thymus, and bone marrow (24) . To confirm successful recombination and loss of expression of Tsc1, we used a LacZ reporter allele. X-gal staining of Tsc1 S1 ). X-gal staining (blue) was also seen in renal tubules of the outer medulla and cortex as well as the paws (Fig. 1A) . Tsc1 cc Darpp-32-Creþ mutant mice had significantly reduced weights compared with littermate controls (Tsc1 ww and Tsc1 cw Darpp-32-Creþ) beginning at P25, a trend that persisted throughout adulthood ( Fig. 1B , P < 0.05, 2-way ANOVA). Similarly, the mutant mice showed significantly reduced survival with median lifespan of 25 weeks, compared with >80 weeks for controls ( Fig. 1C , P < 0.001, log-rank survival).
Necropsy examination demonstrated that renal cystic and tumor lesions were present in all (n ¼ 11) mutant mice at the age of 8 weeks (Fig. 1D) . However, the most striking phenotype seen in these mice was the development of expansile tumor lesions on all 4 paws beginning at post-natal day 21 (Fig. 1D) . These progressive tumors distorted the normal anatomy of the paws.
Histologically, these tumors were composed of pleiomorphic spindle cells arranged in interlacing bundles and whorling patterns. The tumors are highly vascularized and with the spindle cell shape and architecture of these vascular structures, these tumors were identified as hemangiosarcomas ( Fig. 2A-C and Supplementary Fig. S2A ). Mitotic figures were rare. The edges of the tumors were well circumscribed but not encapsulated ( Fig. 2A-C) . By 6 weeks of age, all mutant mice (n ¼ 11) developed visible swelling and abnormal growth on hind paws. Similar tumor formation also occurred in the forepaws but was of smaller extent (data not shown). Control mice (Tsc1 ww and Tsc1 cw Darpp-32-Creþ) showed no evidence of paw tumor formation (Fig. 2D-F) .
Renal pathology
Pathologic evaluation demonstrated that polycystic kidney lesions were also seen at an early age in the Tsc1 cc Darpp-32-Creþ mutant mice, and were detectible in histologic sections by 8 weeks of age (Fig. 3A) . These lesions were cystadenomas (Fig. 3A-C ), similar to those described in both Tsc1 þ/À and Tsc2 þ/À mouse models (17, 18) . They consisted of pure cysts with hyperplastic lining epithelial cells, partially filled cysts with papillary fronds of adenomatous growth, and solid adenomas. These lesions grew rapidly and were extensive by age 4 months, suggesting that they were a major contributor to death in these mice (Fig. 3A -C, for high magnification imaging, see Supplementary Fig. S2B and S2C). Similar to the findings in the paws, there were no observed pathologic abnormalities in the renal tissue of control mice ( Fig.  3D-F) .
Paw hemangiosarcomas provide an easily assessable tumor model of TSC-related tumor growth
The paw hemangiosarcomas developed early in life (<4 months of age) and were easily assessed for size in a noninvasive, quantitative manner as shown by the difference in paw diameter between mutant and control mice (Fig. 4A , P < 0.01 between mutant and control mice at all time points from P40 onward, 2-way ANOVA). We thus saw the potential for using tumor growth to assess therapeutic effectiveness. As an initial proof-of-principle, we treated these mice with rapamycin. Rapamycin was given by intraperitoneal injection at 6 mg/kg 3 times per week for 30 days to a cohort of 11 mice beginning when the largest hemangiosarcoma reached a diameter of 4 mm (average age P102). We observed a significant reduction of 42.5% in hemangiosarcoma diameter after 1 month of therapy ( Fig. 4B , P < 0.001, 1-way ANOVA). When rapamycin was discontinued after 30 days, there was significant regrowth of paw tumors (Fig. 4B , P < 0.001, 1-way ANOVA), consistent with observations in other TSC mouse models (25) and in patients with TSC (10, 13) .
To confirm that activation of mTORC1 was occurring in these tumors and that rapamycin was inhibiting this pathway, we examined tumor lysates by immunoblot analysis. High levels of phospho-S6 Ser240 expression were seen in kidney and paw lysates from vehicle-treated mice (Fig. 4C) . After 1 week of rapamycin treatment, a significant reduction in mTORC1 activation was indicated by reduced phospho-S6 Ser40 staining relative to total S6 Ser240 staining in both kidney (Fig. 4D , P < 0.01, 1-way ANOVA) and paw lysates (Fig. 4D , P < 0.05, 1-way ANOVA). We also examined levels of phosphorylated and total-CAD expression and found that phospho-CAD expression was significantly elevated in vehicle-treated kidney and paw lysates compared with both wild-type and rapamycin-treated lysates ( Fig. 4C and D, P < 0.001, 1-way ANOVA). Histologic analyses of kidneys from mutant mice revealed that a significant reduction in mean cyst diameter was observed in mice treated with rapamycin ( Fig. 5A , P < 0.001, 1-way ANOVA). In addition, there was a significant reduction in mean renal cyst count of rapamycin treated mice (Fig. 5B , P < 0.001, 1-way ANOVA). However, the mean renal cyst count in rapamycintreated mice at 17 weeks was significantly greater than vehicletreated mice at 14 weeks ( Histologic sections of vehicle-treated mutant mice at 17 weeks (Fig. 5C ) and rapamycin-treated mutant mice at 17 weeks (Fig. 5D) show these reductions in cyst size and count. Immunohistochemical analysis of paraffin-embedded tissue sections of kidneys and paws confirmed the high levels of phospho-S6 in these tumors, consistent with mTORC1 activation due to loss of TSC1, and showed that rapamycin treatment eliminated phospho-S6 expression in both kidneys and paws ( Fig. 6A and B, respectively).
VEGF mRNA expression and loss of TSC1
We had noted earlier that the paw hemangiosarcomas are deep red in appearance, suggesting that these tumors are highly vascularized. Prior findings showed that loss of Tsc1 or Tsc2 results in increased VEGF levels, which are associated with tumor development and responsive to rapamycin treatment (26, 27) . Using qPCR, we observed significantly increased VEGF-A mRNA levels in mutant paws but not kidneys, compared with controls ( Fig. 7A , P < 0.001, Student t test). In addition to VEGF-A mRNA levels, we also examined VEGF-C and VEGF-D mRNA levels. Compared with control mutant mice, paws from mutant mice expressed significantly higher amounts of both VEGF-C and VEGF-D mRNA expression ( Fig. 7B and C, P < 0.001 and 0.05, respectively, Student t test). Furthermore, kidneys from mutant mice showed significantly elevated VEGF-D mRNA levels when compared with controls ( Fig. 7C , P < 0.05, Student t test).
Discussion
In this study, we generated a new mouse tumor model in which targeted loss of Tsc1 in both the paws and the kidneys leads to rapid and progressive tumor development. In patients with TSC, hamartomas appear in multiple organs due to random genetic second hits events that lead to complete loss of TSC1 or TSC2 expression and subsequent downstream activation of mTORC1. However, there are still many aspects of tumor formation in TSC (top) and phospho-CAD relative to total CAD (bottom) in both paws and kidneys from wild-type and Tsc1 cc Darpp Cre vehicle-and rapamycin-treated mice. n ¼ 5 for phospho and total-S6-240 experimental groups, n ¼ 4 for each phospho and total-CAD experimental groups. Ã , P < 0.05; ÃÃ , P < 0.01; ÃÃÃ , P < 0.001. that are uncertain, including the cell of origin for most TSC hamartomas, the precise molecular mechanisms of tumor progression, and the exact role of mTORC1 activation in driving tumor growth. Multiple therapeutic strategies have been identified in cell-based or biochemical studies that may provide significant control in TSC tumor growth. In this set of experiments, we took advantage of the fortuitous rapid development of paw and renal tumors in a fully viable mouse model system, Tsc1 cc Darpp-32-Creþ mice. Kidney cystadenomas and paw hemangiosarcomas were seen by P42 and P21, respectively, and enabled rapid assessment of in vivo therapies for TSC tumors. Previous mouse models of TSC-related tumor growth report that extremity tumors (tail, paw, or lip) can take up to 12 months to develop (17) . Furthermore, only 7% of the mutant mice in a previous model (17) developed these extremity tumors. Our conditional knockout mouse model demonstrates full penetrance of paw hemangiosarcomas by 6 weeks of life. Finally, another considerable advantage of this TSC model is that a noninvasive readout of therapeutic strategies can be performed without the need to sacrifice the mouse.
In a preliminary proof of concept drug trial, we demonstrated that rapamycin was an effective therapy for both paw hemangiosarcomas and renal cystadenomas. Most importantly, the progress of treatment could be followed through simple measurement of the paw hemangiosarcomas. Biochemically, we also provide evidence from phospho-S6 and phospho-CAD staining that this effect of rapamycin treatment is likely through inhibition of the hyperactive mTORC1 pathway in Tsc1 cc Darpp-32-Creþ mice. As it is well established that TSC tumor growth is reversed via this mechanism in both humans (10-13) and mice (7, 8) , our model provides the specific development of TSCrelated tumors that can be assessed for responsiveness to therapeutics. Noninvasive measurement of the paw hemangiosarcomas highlights the usefulness of this model, given that the renal phenotype is also responsive to rapamycin treatment, as evidenced by both the biochemical data and reduction in mean cyst diameter and apparent cyst load.
Further support for the conclusion that Tsc1 cc Darpp-32-Creþ mice present a robust model for TSC-related tumor growth is evidenced by VEGF analyses. Beyond TSC-related tumors, VEGF-A expression has been shown to drive tumor angiogenesis and metastasis (28) . Prior research in both TSC cell-based assays (27, 29, 30) and tumor tissue from patients (31) shows that hyperactivation of mTORC1 results in an increased production of hypoxia-inducible factor 1a (HIF1a), a transcription factor which results in an increased expression of HIF-responsive genes such as VEGF-A (29). Furthermore, mouse models have been reported that show increased serum VEGF-A expression in Tsc1 þ/À mice, which was also associated with the extent of tumor development (27, 31) . Interestingly, a reduction in serum VEGF-A expression was observed as a result of short-term rapamycin treatment (4 days at 20 mg/kg), which also was associated with tumor reduction (27) . In our model, we observed an increase in VEGF-A, C, and D mRNA expression in mutant mouse paws, likely due to mTORC1 hyperactivation and subsequent tumor formation. We also observed an increase in VEGF-D mRNA levels from mutant kidneys as compared with kidneys from control mice. Our findings with respect to VEGF mRNA levels support the conclusion that the Tsc1 cc Darpp-32-Creþ mouse is an accurate model of TSC-related tumor growth. As described, previous work has repeatedly shown that VEGF protein levels are elevated in TSC-deficient mice, a phenotype that is rescued by rapamycin treatment (27, 29) . These results have been examined at the protein level, whereas the present findings begin to suggest differences in subtypes of VEGF expression at the mRNA transcript level. While we did not observe significantly increased levels of VEGF-A or C mRNA from kidneys, our analysis of VEGF-D showed the expected increase in VEGF levels from kidneys of mutant mice. VEGF-D has been proposed a potential biomarker of lymphangioleiomyomatosis severity and treatment response (32) . Recent work indicates that both VEGF-A and VEGF-D can be detected in the sera of patients with TSC (33) . Taken together, these results indicate the similar mechanisms may be at play in tumorigenesis in Tsc1 cc Darpp-32-Creþ mouse as in patients with TSC. The present evidence suggests that the Tsc1 cc Darpp-32-Creþ mouse can be an effective tool for the study of pharmaceutical treatments of TSC-related tumors. While there are uncertainties as to both the genetics of these tumors in terms of their abundance as well as their cell size/morphologic features when compared with human tumors, this model presents a valid, quantitative, in vivo model for the testing of potential therapeutics for the treatment of TSC-related tumors.
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